Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 7/20 | 0.52 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19267501 | 0.85 | PKM (0.40) | EGLN1PKMKDM4EALDH1A1POLB | |
| SCHEMBL974330 | 0.76 | PKM (0.47) | EGLN1PKMKDM4EALDH1A1POLB | |
| SCHEMBL17629573 | 0.76 | LMNA (0.60) | KDM4EALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL17629490 | 0.74 | EGLN1 (0.50) | EGLN1PKMKDM4EALDH1A1POLB | |
| SCHEMBL17629620 | 0.71 | KDM4E (0.52) | EGLN1PKMKDM4EALDH1A1POLB | |
| SCHEMBL17629646 | 0.71 | KDM4E (0.49) | EGLN1PKMKDM4EALDH1A1POLB | |
| SCHEMBL17629640 | 0.69 | EGLN1 (1.00) | EGLN1 | |
| SCHEMBL17629597 | 0.67 | EGLN1 (0.77) | EGLN1NPC1MEN1KMT2A | |
| SCHEMBL22838595 | 0.67 | EGLN1 (0.81) | EGLN1 | |
| SCHEMBL17629555 | 0.66 | EGLN1 (0.80) | EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3197455-B1 | INHIBITORS OF HIF PROLYL HYDROXYLASE | MERCK SHARP & DOHME (US) | 2020-12-30 | — | — | EP | disclosed |
| US-10000501-B2 | Inhibitors of HIF prolyl hydroxylase | MERCK SHARP & DOHME CORP. (US) | 2018-06-19 | — | — | US | disclosed |
| US-20170240555-A1 | INHIBITORS OF HIF PROLYL HYDROXYLASE | MERCK SHARP & DOHME CORP. (US) | 2017-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10000501-B2 | Inhibitors of HIF prolyl hydroxylase | HIF1AN, HIF1A, EGLN2 | EGLN1 6/4885PKM 732/4885KDM4E 469/4885 |
| US-20170240555-A1 | INHIBITORS OF HIF PROLYL HYDROXYLASE | HIF1AN, HIF1A, EGLN2 | EGLN1 6/4885PKM 732/4885KDM4E 469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.